Glass House Brands Replay
Cannabis Subscribers CLICK HERE for event details
Takeaways from the Glass House (GLASF) Call:
- The wholesale business, which is 3/4 of revenues, is on allocation.
- The state of CA tracks 100% of sales through the wholesale channel.
- Restructuring the CPG business with a focus on value ($9.99 Allswell 1/8) with a strong margin profile.
- Phase 3 (turning on Greenhouse 2) will have lights for indoor quality (sold at higher wholesale prices), although capital is required for the buildout.
- The MSOS (the AdvisorShares Pure US Cannabis ETF), trades on the New York Stock Exchange Arca (NYSE Arca) and owns GLASF and other cannabis companies. It's logical that after the move to schedule 3, which reduces the friction to list (if that happens), the components of the ETF will trade on the NYSE.
FROM RESCHEDULING TO GENETICS: AN IN-DEPTH LOOK AT THE CANNABIS INDUSTRY WITH SPEEDWELL PARTNERS
Join us for an insightful Cannabis Industry call featuring Brian Moonan and Heather Molloy of Speedwell Partners on 04/04 @ 2 PM.
Cannabis Subscribers CLICK HERE for event details.
As seasoned industry veterans, they founded Speedwell Partners to support and invest in the growth of the legal cannabis industry. The firm is closely managed and optimally structured, utilizing funds and SPVs to maximize efficiencies and transparency while delivering solid returns for investors.
During the call, Brian and Heather will provide an update on private market investment opportunities in the cannabis sector and discuss the themes they are exploring. The discussion will cover several key topics, including:
- The potential impact of rescheduling cannabis to Schedule III on the industry and its growth prospects.
- Public market catalysts include the conversion of Florida and Pennsylvania to adult-use markets and the expected increase in capital spending by large multi-state operators (MSOs).
- An analysis of various business models employed in the industry, including asset-heavy and asset-light approaches used by brands.
- The crucial role of genetics in the cannabis industry and how operators can effectively monetize their proprietary strains.
- The rapid growth of hemp-derived THC products, which are federally legal, and the potential regulatory risks associated with this fast-growing category.
Don't miss this opportunity to learn about the evolving cannabis industry and a leading firm's investment strategies. Join us for this engaging and informative call with Speedwell Partners' Brian Moonan and Heather Molloy.
